by Thamarasee Jeewandara, Medical Xpress Design of IL2-ep13nsEV and its utilization in treating breast cancer. To generate this active immunotherapy, the sEVs from autologous DCs are engineered with surface membrane–bound IL2 by expressing IL2-MFG-E8. This personalization of DC-derived sEV (p13nsEV) is achieved by loading lysed surgically harvested breast cancer cells onto engineered autologous DCs followed...
